← Back to Search

CT Perfusion Imaging for Subarachnoid Hemorrhage (CT-PIPS Trial)

N/A
Waitlist Available
Led By Gwynedd E Pickett, MD
Research Sponsored by Nova Scotia Health Authority
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group

Summary

This trialwill test if CT scans can predict which SAH patients are at risk of stroke from vasospasm, helping to improve their outcomes.

Who is the study for?
This trial is for individuals aged 18-75 who have had a brain hemorrhage due to a ruptured aneurysm and can consent to participate. They must be able to attend follow-up visits and not be in another study, pregnant, breastfeeding, or expected to pass away within 24 hours.
What is being tested?
The trial tests if CT perfusion scans can predict vasospasm—a dangerous narrowing of blood vessels in the brain after hemorrhage—by performing scans when patients are admitted and again on day six.
What are the potential side effects?
CT perfusion involves exposure to radiation similar to that of regular CT scans. Potential side effects include allergic reactions to contrast material used during the scan, such as itching or rash.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
CBF Admit
CBF day 6
CBV Admit
+5 more
Secondary study objectives
Radiation Dose
Other study objectives
Delayed Cerebral Ischemia

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CT PerfusionExperimental Treatment1 Intervention
All patients enrolled in the study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CT Perfusion
2013
N/A
~340

Find a Location

Who is running the clinical trial?

Nova Scotia Health AuthorityLead Sponsor
288 Previous Clinical Trials
94,521 Total Patients Enrolled
Gwynedd PickettLead Sponsor
Gwynedd E Pickett, MDPrincipal InvestigatorCapital District Health Authority, Halifax, Canada

Media Library

CT Perfusion Clinical Trial Eligibility Overview. Trial Name: NCT02056769 — N/A
Subarachnoid Hemorrhage Research Study Groups: CT Perfusion
Subarachnoid Hemorrhage Clinical Trial 2023: CT Perfusion Highlights & Side Effects. Trial Name: NCT02056769 — N/A
CT Perfusion 2023 Treatment Timeline for Medical Study. Trial Name: NCT02056769 — N/A
~5 spots leftby Jun 2026